Under the terms of this latest agreement, Kite will use MaxCyte’s Flow Electroporation technology to help it develop “multiple” CAR-T drug candidates for up to ten targets.
“We're excited to take our relationship with Kite further into product development, providing the company with the ability to leverage MaxCyte's versatile cell engineering platform to enable the power of gene-editing for clinical and commercial development of critical new CAR-T therapeutics,” said MaxCyte president and chief executive Doug Doerfler.
In CAR-T, patient immune cells are extracted, genetically modified with a receptor to target certain cancer cells, then reinfused back into the patient.
This is where MaxCyte’s technology comes in: it allows almost any molecule – such as DNA, RNA or proteins – to be delivered into any cell with minimal cell disturbance.
In return for granting Kite the non-exclusive rights to use its cell engineering platform, Maryland, US-based MaxCyte will receive development and approval milestones and sales-based payments, as well as other licensing fees.
The expansion of the Kite-MaxCyte relationship builds on an existing research agreement announced in November 2018.